The nucleotide NAADP was recently discovered as a second messenger involved in the initiation and propagation of Ca 2؉ signaling in lymphoma T cells, but its impact on primary T cell function is still unknown. An optimized, synthetic, small molecule inhibitor of NAADP action, termed BZ194, was designed and synthesized. antagonism ͉ nucleotide ͉ second messenger ͉ synthesis
The nucleotide NAADP was recently discovered as a second messenger involved in the initiation and propagation of Ca 2؉ signaling in lymphoma T cells, but its impact on primary T cell function is still unknown. An optimized, synthetic, small molecule inhibitor of NAADP action, termed BZ194, was designed and synthesized. Fig. 1A; refs. 7-10) are critically involved in the process of Ca 2ϩ release in T cells. NAADP was discovered by Lee and coworkers as an impurity in nicotinamide adenine dinucleotide phosphate (NADP) preparations and is the most powerful endogenous Ca 2ϩ mobilizing compound known to date (11) . Both plant and animal cells have been shown to respond to application of NAADP (reviewed in refs. [12] [13] [14] . A limited number of reports demonstrated that extracellular stimulation increased intracellular NAADP concentrations, being in accordance with a second messenger function for NAADP (reviewed in refs. [15] [16] [17] .
A controversial issue regarding NAADP is the molecular identity of its receptor. Clearly, in sea urchin eggs, the characterization of NAADP induced Ca 2ϩ release revealed that a receptor/channel different from the InsP 3 receptor or the ryanodine receptor (RyR) is involved (11, 18) . In addition, Lee's group obtained evidence for a non-ER Ca 2ϩ store sensitive to NAADP in stratified sea urchin eggs (19) that was finally identified as a lysosomal compartment (20) (21) (22) (23) . Recent evidence indicates that the novel NAADP receptor on lysosomes is the Ca 2ϩ channel transient receptor potential, mucolipin 1 (TRP-ML1; 24, 25) . In contrast, data obtained by reconstitution of RyR in artificial bilayers suggest direct activation of RyR by NAADP (26, 27) . In addition, NAADP-induced Ca 2ϩ signaling involving RyR was described for MIN6 cells (28) , pancreatic acinar cells (29, 30) , and human T cells (9, 10) . In contrast to the lysosomal store mentioned above, in those cells where RyR involvement was demonstrated, the Ca 2ϩ pool sensitive to NAADP appears to be the SR/ER or ER-related membrane systems like the nuclear envelope rather than lysosomes (26, 27, 29, 31) .
Over the last years, some of us have analyzed the NAADP pathway in Jurkat T lymphocytes in detail, including formation of NAADP (8) , local and global Ca 2ϩ release via RyR (9, 10) , and identification of the NAADP sensitive Ca 2ϩ store residing within the ER (31) . However, the functional role of NAADP in primary T cells has remained unclear due to the inability to specifically interfere with this signaling pathway by means of chemical biological tools. Here we report the synthesis and biological characterization of an optimized NAADP antagonist for T cells, termed BZ194.
Results
A NAADP Antagonist Based on Nicotinic Acid. Microinjection of NAADP into single Jurkat T cells induced robust Ca 2ϩ signaling as described previously (7, 9, 10, 31) . Co-injection of nicotinic acid, but not of nicotinamide, greatly reduced Ca 2ϩ signaling induced by NAADP (Fig. 1B) , indicating that nicotinic acid derivatives might be suitable for chemical biological intervention as NAADP antagonists and for possible drug design. Since NAADP is highly active in Ca 2ϩ release, while the structurally related parent compound NADP ( Fig. 1 A) is inactive (11), it is very likely to be the nicotinic acid moiety that interferes with NAADP-mediated Ca 2ϩ signaling. Indeed, since cellular uptake of the polar nicotinic acid is slow and this molecule is obviously intracellularly channeled into biosynthesis of nicotinamide adenine dinucleotide (NAD), we reasoned that design of a membrane-permeant analogue should be a powerful approach toward targeting the NAADP/Ca 2ϩ signaling pathway. NAADP itself is clearly too polar to be a useful starting point for any chemical design, but the nicotinic acid moiety is ideally based from which to develop modified drug-like small molecule NAADP modulators. Consequently, prototype nicotinic acid derivatives were synthesized by alkylation of nicotinic acid using 2-bromoacetylamides as the alkylating agents. From a library of alkylated nicotinic acid derivatives (representative examples are shown in Fig.  S1 A) the N-alkylated 8-carbon side chain derivative, 3-carboxyl-1-octylcarbamoylmethyl-pyridinium (BZ194) emerged as a potent antagonist of proliferation of effector T cells (Fig. S1B) . Importantly, when BZ194 was co-injected into Jurkat T cells together with NAADP, both the initial Ca 2ϩ peak and the sustained Ca 2ϩ plateau observed upon injection of NAADP were concentrationdependently blocked resulting in an IC 50 in the low micromolar range ( Fig. 1 C and D) . Notably, BZ194 co-injected together with the Ca 2ϩ mobilizing second messengers InsP 3 or cADPR ( Fig. 1E and Fig. S2 A and B) did not inhibit their activity suggesting high specificity of BZ194 toward the NAADP/Ca 2ϩ signaling pathway.
RyR1 Activation by NAADP. Previously, we have presented evidence for NAADP targeting the RyR (9, 10), including use of single channel recordings (26) . To extend these results, we used highly purified RyR1 ( Fig. 2A) , and analyzed high-affinity [ 3 H]ryanodine binding, which is proportional to channel opening (32) . NAADP significantly accelerated the association of [ 3 H]ryanodine to the purified RyR1 (Fig. 2B) . While BZ194 had no effect on the basal [ 3 H]ryanodine binding, the NAADP-induced increment in radioligand binding was completely abrogated. Importantly, the dissociation of [ 3 H]ryanodine was not influenced by BZ194 (Fig. 2C ) whereas the dissociation from NAADP preactivated RyR1 was significantly accelerated, indicating an allosteric regulation. The basal equilibrium binding was not significantly altered by increasing concentrations of BZ194 (Fig. 2D ). However, [ 3 H]ryanodine binding stimulated by NAADP was antagonized by BZ194 in a concentration-dependent manner (Fig. 2D) . The IC 50 value was comparable with that observed for Ca 2ϩ release inhibition in the native cellular system (Fig. 1D) . Hence, these results are indicative of direct targeting of RyR1 by both NAADP and BZ194. (Fig. 3A ). RyR1 showed a significant co-localization with an ER marker, while RyR2 was not detected (Fig. 3A) .
BZ194-type compounds with varying lengths and types of side chains R1 and/or R2 ( Fig. S1 A), were tested with intact T MBP cells using antigen-induced proliferation as read-out (Fig. S1B ). Using iterative exploration of substituents the single octyl side chain of BZ194 proved to be most suitable for membrane permeability and neither a longer side chain, for example, 10 carbon atoms in BZ71, nor a lack of side chain in CMA008 had any effect on T MBP cell proliferation ( Fig. S1 A and B) . Interestingly, the other active analog identified, the disubstituted BZ52, possesses the same number of side chain carbon atoms, but distributed over 2 centers. BZ194 blocked Ca 2ϩ signaling in intact T MBP cells upon stimulation with the specific antigen. Using astrocytes pulsed with MBP, Ca 2ϩ signaling was recorded upon formation of the immunological synapse (Fig. 3B ). While presentation of MBP by the astrocytes resulted in substantial Ca 2ϩ signaling, reaching a plateau phase within about 4 min, BZ194 significantly diminished this response ( Fig. 3 B and C monoclonal antibody, and subsequent crosslinking of the primary antibody was also sensitive to BZ194. Both the initial Ca 2ϩ peak and the sustained Ca 2ϩ plateau were reduced in a concentrationdependent fashion with the plateau being more sensitive compared with the initial peak ( Fig. 3 D and E) . The antagonistic effect of BZ194 required preincubation periods (Fig. 3F) Signaling. Calcium signaling in T cells activates Ca 2ϩ /calmodulin dependent phosphatase calcineurin leading to ''nuclear factor of T cells'' (NFAT) dephosphorylation and translocation into the nucleus. BZ194 significantly reduced nuclear translocation of NFAT following combined stimulation of rat T MBP cells with anti-CD3 and anti-CD28 antibodies (Fig. 4 A and B) .
Furthermore, BZ194 efficiently suppressed antigen-induced production of the major T cell cytokine IL-2, as determined on the mRNA and protein levels (Fig. 4 C and D) . Importantly, BZ194-mediated regulation of IL-2 levels was reversible. Re-stimulation of the suppressed T cells in the absence of BZ194 led to complete reconstitution of the original cytokine profile (Fig. S3) . In a similar fashion as for rat T cells, in human MBP-specific T-cell clones a decrease in IL-2 mRNA, IL-2 production and proliferation was observed upon preincubation with BZ194 (Fig. S4) .
The NAADP antagonist suppressed antigen-induced T-cell proliferation at concentrations higher than 50 M. As expected, the highly polar and membrane impermeable parent compound nicotinic acid was ineffective (Fig. S1B ). Non-stimulated T MBP cells tolerated prolonged treatment (48 h) with BZ194; furthermore, T cells which had previously been suppressed by BZ194 remained responsive to their antigen, when re-challenged with antigenpulsed, antigen-presenting cells (APCs) after wash-out of BZ194 (Fig. S5) . Moreover, BZ194 treatment 48 h after stimulation did not impair T-cell proliferation and did not induce increased cell death (Fig. S5) . Together with the microinjection (Fig. 1 B-E) (Fig. 2) , these data indicate very specific targeting of RyR1 since (i) wash-out of BZ194 reverted the inhibition, and (ii) late stages of T-cell activation (Ͼ48h) were unaffected by addition of BZ194. This interpretation was further substantiated by directly demonstrating that BZ194 did not affect cellular signaling cascades beyond Ca 2ϩ signaling. Bypassing early Ca 2ϩ signaling by stimulating T MBP cells with Ca 2ϩ ionophore ionomycin either in combination with anti-CD3/anti-CD28 antibodies or with phorbol ester (PMA) rendered the T cells nonsusceptible to BZ194 inhibition (Fig. 4E) . Similar inhibition of proliferation by BZ194 treatment was observed in ovalbumin and S100␤-specific rat T cells (Fig. S6 ).
Discussion
Recent reports on the role of Ca 2ϩ signaling in activation of T cells indicate a complex network involving NAADP as initial Ca 2ϩ trigger (7-10, reviewed in ref. 17 ). Here we report that the nicotinic acid residue of NAADP is suitable as a starting point for the development of NAADP antagonists. In sea urchin eggs, the 2Ј-phospho-group of the ribose bound to the adenine-linked ribose, the 6-NH 2 group of adenine and the nicotinic acid moiety were identified as important structural elements for Ca 2ϩ release (33) . Since these 3 structural moieties are distributed over the whole NAADP molecule, it was deemed very difficult to design a potential antagonist molecule comprising alterations in all 3 structural elements. Thus, we started with simple N-alkylated analogues of nicotinic acid to which lipophilic groups to enhance membrane permeability were covalently bound. Additionally, we explored other substitutions around the aromatic nucleus to optimize activity. A range of potential ligands was synthesized to gain the optimal balance between cellular permeability, activity, and physicochemical properties. In structure-activity studies, we found that little variation beyond a moderate-sized hydrophobic side chain was tolerated by T cells. In fact, the 8 carbon-side chain analog BZ194 was effective with an IC 50 around 100 M. This extra hydrophobicity in BZ194 can also be distributed over 2 substituents on nitrogen atoms giving a similar effect in BZ52 and thus is consistent without further optimization. In contrast to BZ194 and BZ52, BZ23, an analog with a substituted aromatic side chain, enhanced proliferation of T MBP cells. The molecular mechanism underlying this interesting observation will be the subject of further experiments.
One obvious concern in using pharmacological compounds is the question of their specificity. To this end, we excluded that BZ194 affects the other known Ca 2ϩ -mobilizing pathways, that is InsP 3 -or cADPR-dependent Ca 2ϩ release, or capacitative Ca 2ϩ entry. Furthermore, (i) bypassing inhibition of NAADP signaling by Ca 2ϩ ionophore, (ii) reversibility of inhibition of proliferation upon wash-out of BZ194, and (iii) lack of effect of BZ194 addition at later time points of T-cell activation altogether strongly suggest high specificity of the drug used. Finally, we also ensured that BZ194 does not block physiological Ca 2ϩ signaling via different mechanisms in other cell types, for example, in electrically paced mouse cardiac myocytes or human HeLa cells stimulated via G protein coupled muscarinic acetylcholine receptors. Recently, 1-carbamoylmethyl-3-carboxy pyridinium iodide (abbreviated CMA008; see Fig. S1 A and B) was shown to antagonize NAADP effects in sea urchin eggs and murine pancreatic acinar cells (34) . Although this analog is structurally related to BZ194, no inhibitory activity in T cells was observed. This non-sensitivity of T cells vs. sensitivity of pancreatic acinar cells reflects the different nature of the target Ca 2ϩ store and the NAADP receptor involved. While a novel NAADP-sensitive channel has been proposed for those cell types with acidic stores sensitive to NAADP (20) (21) (22) (23) (24) (25) , strong evidence for RyR1 as NAADP target was obtained in T cells since NAADP modulated high-affinity [ 3 H]ryanodine binding. This in turn reflects RyR1 channel opening, as the radioligand binds to the open conformation of the ion channel (32, (35) (36) (37) . Importantly, the BZ194 concentrations needed to suppress NAADP induced Ca 2ϩ release in Jurkat T lymphocytes (Fig. 1D) equal that needed to prevent NAADP stimulated [ 3 H]ryanodine binding (Fig. 2B) . Thus, these data suggest that the RyR1 is the primary target for BZ194. RyR3 is expressed to a lesser extent in effector T cells. Gene silencing experiments in Jurkat T cells indicate that RyR3 is targeted by cADPR (38) . However, defining the precise interaction between cADPR and any RyR subtype, as shown in Fig. 2 of this report for NAADP and highly purified RyR1, requires further extensive experiments. Alternatively proposed NAADP targets, such as TRP-ML 1 (24, 25) that are localized to lysosomes, do not appear to play a major role in T cells since the ER rather than lysosomes are involved in NAADP mediated Ca 2ϩ signaling in T cells (31) .
The present study complements published models on temporal events of Ca 2ϩ release. We show here that NAADP via RyR1 activation acts as the initializing trigger, which controls further Ca 2ϩ release events by supplying local Ca 2ϩ signals for Ca 2ϩ induced Ca 2ϩ release to amplify InsP 3 -and cADPR-induced Ca 2ϩ release. NAADP mediated Ca 2ϩ release starts rapidly within a few seconds upon TCR/CD3 ligation (8) . By contrast, InsP 3 -and cADPRmediated releases appear within a few minutes (39) or within tens of minutes, respectively (6) . A possible reason for this complex regulatory Ca 2ϩ release network may be the need for temporal checkpoints, at which the T cell, based upon the input via the TCR/CD3 complex and diverse co-receptors, can control whether to proceed with activation or not (40) . The decision whether to continue or to stop Ca 2ϩ signaling may ultimately result in cell proliferation and exertion of effector functions, or it may drive the T cell into a state of unresponsiveness or cell death. The NAADP/ Ca 2ϩ signaling pathway seems to control this decision, since expression of the major cytokine involved in T cell proliferation, IL-2, depends on a full, NAADP-initiated Ca 2ϩ response. If the NAADP pathway is blocked by specific inhibitors, Ca 2ϩ signaling is only partially activated. Therefore, it does not provide a sufficient long-lasting increase in the free cytosolic Ca 2ϩ concentration to allow Ca 2ϩ /calmodulin-and calcineurin-dependent translocation of NFAT into the nucleus (41). , n ϭ 8 -9 ). (G) Cells were preincubated with 1 mM BZ194 overnight and thapsigargin (1 mM, arrow) was added to induce capacitative Ca 2ϩ signaling; mean data Ϯ SEM (n ϭ 9) are summarized in H. * , P Յ 0.05 according to Student's t test; ns, not significant.
By establishing highly specific NAADP antagonists, we demonstrate here that the NAADP/Ca 2ϩ pathway is critically involved in early activation events of antigen-specific CD4 ϩ effector T cells. NAADP antagonist BZ194 blocked the NAADP stimulated RyR1 Ca 2ϩ release and, as a secondary and indirect effect, all downstream Ca 2ϩ signaling events depending on initial trigger Ca 2ϩ as coagonist were diminished. Thereby, NAADP antagonist BZ194 specifically interfered with the interactions of effector T cells with APCs. Importantly, while down-modulating Ca 2ϩ signaling and effector reactions of T cells, BZ194 did not show any major unspecific effects. This may in part be explained by the virtual absence of effects of BZ194 on basal equilibrium [ 3 H]ryanodine binding or dissociation kinetics (Fig. 2) . BZ194 is thus an inhibitor of the RyR1, which accesses the ion channel in the presence of NAADP, implying that channel opening is necessary for its inhibitory action. The fact that BZ194 had virtually no inhibitory effect on basal binding (Fig. 2 B and D) supports this assumption. In terms of potential clinical usage such a mechanism of action may result in less effects on the basal RyR1 activity, but increased inhibition if the RyR1 is activated. Thus, one may assume that side effects by such a mechanism of action could be reduced compared with a stateindependent inhibitor of the RyR1.
Therefore, the involvement of the NAADP/Ca 2ϩ signaling pathway in a primary T-cell model relevant for the pathogenic context of T cell-mediated autoimmunity has been demonstrated in vitro using a purpose-designed and optimized synthetic small molecule antagonist. The use of such NAADP antagonists in the corresponding animal model of experimental autoimmune encephalomyelitis (EAE) is the subject of ongoing investigations. Treatment with BZ194 in vivo was found to significantly ameliorate clinical disease. Thus, this approach may result in additional therapeutic agents for treating autoimmune diseases such as multiple sclerosis.
Methods
Materials. NAADP was supplied by Sigma. cADPR and InsP3 were obtained from Biolog. All reagents and solvents were of commercial quality and were used directly unless otherwise described.
Synthesis of 3-Carboxy-1-octylcarbamoylmethyl-pyridinium Bromide (BZ194).
For synthesis, nicotinic acid (1.62 mmol) and 2-bromo-N-octylacetamide (1.62 mmol) were dissolved in dry dimethylformamide (DMF, 4 mL) and the reaction solution was heated at 65°C overnight in the dark. DMF was evaporated in vacuo and the resulting residue was dissolved in a small amount of methanol. The crude compound was precipitated by dropwise addition of ether. 3-Carboxy-1-octylcarbamoylmethylpyridinium was further purified by flash column chromatography (0 -10% methanol against dichlormethane) and was crystallized in methanol and acetone. The compound exhibited spectroscopic and analytical properties commensurate with its structure using standard techniques as detailed in the SI Methods.
High-Affinity [ 3 H]Ryanodine
Binding. RyR1 was purified from rabbit skeletal muscle (42) . Purity of the RyR1 preparation was controlled by SDS/PAGE and silver staining (43) . High-affinity [ 3 H]ryanodine binding was carried out with 7.5-20 g purified RyR1, which was incubated for the indicated times at 30°C in a buffer containing 20 mM Hepes (pH 7.4), 140 mM KCl, 50 mM NaCl, 2.5% phosphatidyl choline, 7 mM CHAPS, and 20 nM [ 3 H]ryanodine supplemented by protease inhibitors (1 M leupeptin, 1 M aprotinin, and 100 M Pefablock). The free calcium concentration was adjusted to 6 M by ratio of CaCl2 and EGTA. The reactions were terminated by filtration. Specific binding was determined by subtraction of nonspecific binding in the presence of 20 M ryanodine (42) .
Generation and Culturing of T Cells. Jurkat lymphoma T cells (clone JMP) were cultured as described previously (43) . Rat antigen-specific T cell clones were obtained from lymph node preparations of immunized Lewis rats. Stimulation, expansion, and culture of specific rat T cells were conducted under conditions as described (44) . Details concerning generation of MBP-specific CD4 ϩ T cells (TMBP) retrovirally engineered to express the marker gene EGFP are provided in the SI Methods.
Cytosolic Ca 2؉ Measurements. Both Jurkat T lymphoma and rat TMBP cells were loaded with Fura-2/AM (Calbiochem) as described (44) and kept in the dark at room temperature until use. Intracellular Ca 2ϩ ([Ca 2ϩ ]i) was determined in suspensions of Fura-2-loaded rat T MBP cells which had been preincubated with BZ194 or DMSO at the indicated concentrations for at least 8 h in a Hitachi F-2000 fluorometer as described previously (46) . More detailed information about the ratiometric Ca 2ϩ measuring method is provided in the SI Methods.
Microinjections. Intracellular injections were carried out as described previously (7, 9, 10, 31). More detailed information is provided in the SI Methods. Proliferation Assays of Cultured T Cells. Antigen-specific rat T cells (TMBP and T OVA) were co-cultured for 48 h in 96-well plates (in DMEM 1% rat serum) with irradiated professional thymic APCs as previously described (45) , in presence of specific or control antigen (10 g/mL MBP or OVA) and BZ194 in DMSO or DMSO alone. Amplification of T MBP-GFP cells was measured by cytofluorometry. Their numbers were determined in relation to a known absolute number of added phycoerythrin-labeled plastic beads (Becton Dickinson). The amplification rate was calculated in relation to the T GFP cell numbers at day 0. Alternatively, [ 3 H]-2Ј-deoxy-thymidine ([ 3 H]dT; 2 Ci/mmol; Amersham) incorporation was used to evaluate proliferation. Radioactivity was determined as described (47) . More detailed information about proliferation assays in rat T cells is provided in the SI Methods.
Quantitative PCR and ELISAs. Detailed information is provided in the SI Methods. 
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